Telix Pharmaceuticals Limited (ASX: TLX) operates as a biotechnology company. The Company develops and commercializes molecularly-targeted radiation therapy for the treatment of prostate, renal, and brain cancer. Telix Pharmaceuticals serves patients worldwide.
On 09 January 2019, the company released its detailed program update wherein it highlighted about FY18 activities and its future business prospect. As per the presentation, the company has developed diagnostic and therapeutic radiopharmaceuticals for the purpose of treating Metastatic prostate cancer, Renal (kidney) cell cancer, and Brain cancer (glioblastoma).
On the other hand, the company also disclosed its multiple partnerships with leading global healthcare companies such as CardinalHealth, CYCLOTEK, medi+physics, GenesisCare, ISOLOGIC, ENDOCYTE, and JFE. Following the release, the share price of the company increased by 1.389% on January 09, 2019.
On the front of Antibody imaging, the company will be taking the help of PET for the purpose diagnosing renal cancer. Imaging agent CA-IX is a cell-surface antigen that is highly over-expressed in renal cell cancer, particularly the clear cell phenotype. This imaging technology has undergone a Phase III trial (REDECT trial, NCT00606632) with an iodinated (124I) version of the imaging agent (Wilex AG).
Regarding the diagnosis of the metastatic clear cell renal cell cancer, the initial findings have shown that there are 150,000 patients in the US from routine abdominal CT. The need of the hour in this segment is the imaging biomarkers that show disease aggressiveness. RCC is an aggressive cancer category; hence one needs to know at continuous intervals if treatment is working. This Imaging gives a highly accurate picture of treatment efficacy.
Telix is holding on with a pipeline of multibillion dollars opportunity with the following in innovations in the oncology space:
- TLX 591: Metastic prostate cancer radionuclide therapy is a $2 Bn opportunity in the late stage of the disease alone.
- TLX101: The treatment of GBM is a $300m market opportunity with few beneficial options.
- TLX591–CDx: Prostate cancer imaging (targeting PSMA) is the biggest new indication for PET/CT in radiology and represents a $500m opportunity in the US alone.
- TLX250-CDx: Renal cancer patients are often mis-staged, a niche $250m opportunity with no real competition.
- TLX250: Firm’s therapy for patients that have progressed from immunotherapy is a $400-500m opportunity.
In FY 2018, the company took its M&A activity and strategic partnerships to a whole new level, as the company was focussed upon the building of leading pipeline of radiopharmaceutical products and technologies.
The company had acquired Atlab pharma for a consideration of US $10m in scrip. The purpose of this acquisition was to gain access to clinical data and patent portfolio in relation to huJ591 anti-PSMA mAb, particularly for combination therapy with anti-androgens and image-based patient selection.
The firm also acquired the ANMI (Advanced Nuclear Medicine Ingredient) for a consideration of €5.1 Mn. The purpose of the purchase was to gain rights to PSMA imaging technology and access to an early-stage pipeline of “kit” technologies for other oncology application areas as well as talent acquisition.
The company has got a humongous opportunity in the US as the Prostate cancer is the most common male cancer in the US with 160,000 new cases diagnosed annually in men over 50 years of age. About three million men are living with prostate cancer in the states.
Meanwhile, the stock price of the company has risen by 9.09 percent in the past six months as on 8 January 2019. TLX’s shares traded at $0.73 with the market capitalization of circa $157.22 Mn as on 9 January 2019.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.